Ascletis Pharma has dosed the first obese or overweight subjects in the 13-week, multi-centre US Phase IIa trial of ASC30.

As obesity management draws awareness and weight-loss injections are launched in India, hospitals are offering customised ...

MASLD, a liver disease linked to obesity and poor lifestyle, is rising among children. Often symptomless early on, it can ...

The British drug agency is monitoring a possible increase in cases of the disease, although there is no data yet to warrant ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

Improving access and affordability could be transformative for public health, given that about 88% of Americans are ...

Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today that the first participants with obesity or overweight with at least one weight-related comorbidity have been dosed in a U.S. 13-week ...

The Delhi High Court has instructed India's drug regulator to address concerns about the approval process for drugs like ...

VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.

After decades of setbacks, Alzheimer’s drug development is expanding beyond anti-amyloids, with a record number of trials and ...

MIRA is advancing complementary non-opioid therapies for two of the largest pain markets MIAMI, FLORIDA / ACCESS Newswire / ...

Just two days after Novo Nordisk launched Wegovy (semaglutide 2.4 mg) in India, Eli Lilly received regulatory approval for the KwikPen® format of its rival therapy Mounjaro (tirzepatide) ...